Oxford BioMedica

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Oxford BioMedica plc
Public company (LSEOXB)
Industry Pharma
Founded 1995
Revenue £15,900,000 (May 2016)[1]
£−14,100,000 (May 2016)[1]
Number of employees
250[2]
Website www.oxfordbiomedica.co.uk

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development and commercialisation of innovative gene-based medicines. It was established in 1995 as a spin out from Oxford University.[3] The lead product is TroVax, a therapeutic cancer vaccine for multiple solid cancers, which is in Phase III development in collaboration with Sanofi-Aventis. TroVax failed in a key kidney cancer test in 2008 which caused a dramatic drop in Oxford BioMedica's share price[4] The Company’s advanced development pipeline includes treatments for cancer, Parkinson's disease and retinopathy. The company's early stage development pipeline includes preclinical candidates for Stargardt disease, motor neuron disease, spinal muscular atrophy and AIDS.[5]

Finance[edit]

The company had raised a total of £137 million to fund its research and clinical programmes. The IPO on the Alternative Investment Market of the London Stock Exchange in December 1996 raised £5.1 million.

A further £6 million was raised by a rights issue and placing in March/April 1998, £3.6 million by a rights issue in March 1999, £5.2 million in a Placing in January 2000 and £8.8 million in a Placing in August 2000.

Oxford BioMedica's move to the official list of the London Stock Exchange was completed in April 2001 along with a £35.5 million fund raising, before costs, from a placing and open offer.

A Rights Issue for £22.1 million, before costs, was completed in October 2003. A further share offering in December 2005 raised £30.1 million before expenses, including an investment of £2.9 million by Sigma-Aldrich [6][better source needed]. A placing and open offer in December 2010 raised £20 million.

References[edit]

  1. ^ a b "Annual Report and Accounts 2015" (PDF). Oxford BioMedica. Retrieved 25 December 2016. 
  2. ^ "Oxford BioMedica Notes Findings Reported by Novartis on CTL-019 at 58th American Society of Hematology Annual Meeting". Consilium Strategic Communications Limited. 5 December 2016. Retrieved 25 December 2016. 
  3. ^ Hoover's | A D&B Company. Hoovers.com.
  4. ^ http://business.timesonline.co.uk/tol/business/industry_sectors/health/article4319051.ece
  5. ^ [1] Archived 22 April 2009 at the Wayback Machine.
  6. ^ [2] Archived 22 April 2009 at the Wayback Machine.